13 June 2011 - Quotient Amersham* Radiochemicals has today officially changed its name to Quotient Custom Radiolabelling following two years of significant expansion and investment in a £15m state-of-the-art laboratory in Cardiff.
The business was acquired by Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical and biotechnology clients worldwide, from GE Healthcare in 2009 to continue its growth in metabolism and carbon-14 (14C) enabled drug development capabilities.
Over the past two years, the Quotient radiochemistry team has leveraged the Amersham radiolabelling legacy and continues to enjoy a world leading position in custom radiosynthesis of 14C and Tritium. More than 70 specialist radiosynthesis chemists, which made up the Amersham Radiolabeling Services team, have transferred to Quotient and operate from the purpose-built radiosynthesis facility in Cardiff.
Stephen Lewinton, MD for Chemistry and Metabolism at Quotient Bioresearch, commented: “The past two years have been particularly exciting for Quotient and it’s with a great sense of accomplishment that we officially change name to Quotient Custom Radiolabelling.
“We inherited an enviable legacy from Amersham Radiolabeling Services and through our investment in the business and in the new facility, we’re able to provide a fully-integrated quick response service for our customers.”
Quotient provides a unique and comprehensive range of early-stage drug development services including custom radiolabelled drug compounds, in vivo and in vitro metabolism studies, clinical studies and bioanalytical services to a broad range of customers across Europe, US and Japan.
For further information about Quotient Bioresearch, visit the website at www.quotientbioresearch.com, or email info@quotientbioresearch.com.
*Amersham is a trademark of GE Healthcare
